TWiV 817: COVID-19 clinical update #84 with Dr. Daniel Griffin

In COVID-19 clinical update #84, Dr. Griffin discusses childrens' antibody response to vaccination, phase 3 results of Novavax vaccine, heterologous vaccination, antithrombotic therapy, EUA for molnupiravir, phase 3 results of AZD7442, serum ferritin levels and outcomes, heparin therapy, and WHO strategy for global vaccination. Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free): iTunes , Google Podcasts , RSS , email Become a patron of TWiV! Links for this episode Antibody profiles after mRNA vaccination in children (bioRxiv) Novavax vaccine phase 3 results (medRxiv) Heterologous vaccine boosters (medRxiv) Antithrombotic therapy outcomes (JAMA) Molnupiravir EUA submitted (Merck) AZD7442 phase 3 results (AstraZeneca) Serum ferritin levels and disease outcome (JAMA) Heparin efficacy (JAMA) WHO strategy to vaccinate world (WHO) Letters read on TWiV 817 Timestamps by Jolene . Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]